Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values

Novocure’s mission and values support its overarching patient-forward
vision to make a difference in cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#fromdayoneforwardlt;/agt;–Novocure (NASDAQ: NVCR) announced today the publication of its 2018
Annual Report featuring its vision, mission and values, employee stories
and videos, business highlights and selected financial information. In
2018, Novocure made a commitment to put into words its vision, mission
and values as part of its corporate objective of investing in its people
and culture.

The publication of the 2018 Annual Report marks the public debut of
Novocure’s newly defined vision, mission and values. Novocure launched
its vision, mission and values internally to its nearly 600 employees at
the end of 2018.

“We as a company are very proud of our vision, mission and values that
have been a part of who we are from day one,” said Novocure CEO Asaf
Danziger. “We believe our values, the core traits that we share, will
help us to achieve our mission of striving to extend survival in some of
the most aggressive forms of cancer.”

To view the digital version of our 2018 Annual Report, please visit

About Novocure

Novocure is a global oncology company working to extend survival in some
of the most aggressive forms of cancer by developing and commercializing
its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is
a cancer therapy that uses electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s commercialized
product is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in mesothelioma, brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit
or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory submission and approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 28, 2019, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.


Media and Investor Contact:
Ashley Cordova